Cowen restated their hold rating on shares of Pacira Biosciences (NASDAQ:PCRX) in a research note published on Thursday, AnalystRatings.com reports. Cowen currently has a $41.00 price target on the stock.
A number of other analysts also recently weighed in on the company. Jefferies Financial Group set a $60.00 target price on Pacira Biosciences and gave the stock a buy rating in a research report on Tuesday, October 8th. Stifel Nicolaus set a $42.00 target price on Pacira Biosciences and gave the stock a hold rating in a research report on Friday, August 9th. BMO Capital Markets dropped their target price on Pacira Biosciences from $46.00 to $43.00 and set a market perform rating for the company in a research report on Friday, August 9th. BTIG Research began coverage on Pacira Biosciences in a research report on Wednesday. They issued a buy rating and a $56.00 price objective for the company. Finally, Zacks Investment Research upgraded Pacira Biosciences from a sell rating to a hold rating and set a $47.00 price objective for the company in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $52.55.
PCRX traded up $1.40 during trading hours on Thursday, hitting $44.02. The stock had a trading volume of 711,200 shares, compared to its average volume of 631,161. The company’s fifty day simple moving average is $39.20 and its 200 day simple moving average is $41.12. The stock has a market cap of $1.76 billion, a PE ratio of 151.79, a price-to-earnings-growth ratio of 1.96 and a beta of 1.13. Pacira Biosciences has a 1 year low of $34.64 and a 1 year high of $50.90. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99.
Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, November 7th. The company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.35. The company had revenue of $104.69 million during the quarter, compared to the consensus estimate of $104.88 million. Pacira Biosciences had a return on equity of 8.62% and a net margin of 2.04%. Pacira Biosciences’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.31 EPS. As a group, equities analysts expect that Pacira Biosciences will post 0.63 EPS for the current year.
In other news, insider Kristen Marie Williams sold 6,252 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total transaction of $246,891.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David M. Stack sold 12,849 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $39.15, for a total value of $503,038.35. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. HM Payson & Co. purchased a new position in shares of Pacira Biosciences during the second quarter valued at approximately $39,000. Usca Ria LLC purchased a new position in shares of Pacira Biosciences during the third quarter valued at approximately $38,000. C M Bidwell & Associates Ltd. purchased a new position in shares of Pacira Biosciences during the second quarter valued at approximately $44,000. LS Investment Advisors LLC purchased a new position in shares of Pacira Biosciences during the third quarter valued at approximately $50,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Pacira Biosciences by 414.7% during the second quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock valued at $63,000 after buying an additional 1,157 shares during the period. 99.13% of the stock is currently owned by hedge funds and other institutional investors.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Further Reading: Fundamental Analysis
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.